Opening: Real Consultation Scenario (Mechanism 1)
Clinic Scenario Ms. Wang, 39 years old, had three previous high-quality blastocyst transfers without pregnancy. Endometrial thickness, morphology, and blood flow ultrasound were normal, embryo chromosomal testing (PGT-A) showed no abnormalities, and immune/coagulation-related tests revealed no clear issues. She sat in front of me, holding a stack of reports, and asked:
"Doctor, I've been tested for everything, and everything is said to be normal, but I just can't get pregnant. I heard there is an ERT technology that can check the endometrium. Am I suitable for it? How good is this technology in China?"
What is ERT? Is ERT technology mature in China?
ERT (Endometrial Receptivity Test) analyzes the gene expression profile of endometrial tissue to determine whether the endometrium is in the optimal "window of implantation" (WOI) for embryo implantation and whether the window is displaced. ERT technology has been clinically available in China since around 2018. Currently, several reproductive centers offer it, including domestically developed testing platforms (e.g., BGI, CapitalBio) and imported ERA technology. Overall, ERT in China has transitioned from the research phase to clinical application, but not all reproductive centers have the testing capability, and testing standards and interpretation experience are still being accumulated.
When is ERT suitable? Primarily for patients with recurrent implantation failure (RIF), especially those who have transferred high-quality blastocysts (including PGT-A normal embryos) without implantation and have ruled out common causes such as uterine cavity abnormalities, immune/coagulation issues, and endocrine abnormalities. When is it not suitable? Patients undergoing their first transfer, those with significant organic uterine pathology (e.g., adhesions, polyps, fibroids) that has not been treated, or those with a low probability of window displacement are generally not recommended to prioritize ERT. A systematic evaluation by a reproductive specialist is necessary before testing to avoid over-examination.
Interpretation of ERT Test Indicators: Gene Expression and Window of Implantation Judgment
The core of ERT testing is to analyze the expression levels of a set of genes related to receptivity in endometrial tissue, typically including hundreds of genes (the gene panel varies slightly between platforms). The expression profile is compared to a reference model of normal receptive endometrium using algorithms, yielding one of the following three conclusions:
| Test Conclusion | Meaning | Clinical Recommendation |
|---|---|---|
| Pre-receptive | The endometrium has not yet entered the window of implantation; the sampling time is too early. | Delay the transfer time; adjust the duration of progesterone use based on the results. |
| Receptive | The endometrium is in the window of implantation; the sampling time matches the window. | Proceed with transfer according to the original or standard protocol. |
| Post-receptive | The endometrium has passed the window of implantation; the sampling time is too late. | Advance the transfer time; shorten the duration of progesterone exposure. |
Some reports also provide subcategories such as "non-receptive" or "displaced window of implantation," for example, displacement >12 hours or 24 hours, to help doctors precisely adjust the transfer plan. It is important to note that the accuracy of ERT testing is not 100%; false negatives and false positives are possible. Interpretation should be combined with endometrial morphology, ultrasound characteristics, and the patient's previous cycle performance for a comprehensive assessment.
Why Does the Window of Implantation Shift? Analysis of Common Causes
The mechanism of endometrial window displacement is not fully understood, but current research suggests it is related to the following factors:
- Endocrine factors: Abnormal estrogen levels during the follicular phase, insufficient or prematurely elevated progesterone during the luteal phase, leading to asynchrony between endometrial development and embryo development.
- Local endometrial microenvironment: Chronic endometritis (especially pathogen infection or dysbiosis), insufficient endometrial blood supply, and local cytokine network disorders.
- Genetic and epigenetic factors: Some patients have gene polymorphisms or methylation abnormalities related to receptivity, leading to window displacement.
- Impact of hormone replacement therapy (HRT) protocols: Exogenous hormone regimens, the type and dose of progesterone, and the duration of medication can all affect the timing of the window opening.
- Age factor: The probability of changes in the endometrial receptivity gene expression profile increases in women over 38 years old, and the risk of window displacement is relatively higher.
Clinically, about 20% to 35% of patients with recurrent implantation failure have window displacement, which is the core value of ERT testing. However, it should be clear that window displacement is only one of the reasons for implantation failure, not the sole cause.
Details Most Easily Overlooked in ERT Testing
Based on daily clinical experience, the following details significantly impact the accuracy and clinical value of ERT results but are often overlooked:
- Precise timing of sampling: ERT requires endometrial biopsy at a specific time point. In natural cycles, it is usually on the 7th day after the LH surge or the 7th day after ovulation; in HRT cycles, it is on a specific day after progesterone administration (usually day 5 or 6). A sampling time deviation of more than 2 hours may affect result interpretation.
- No progesterone use before sampling: In some cycle protocols, if progesterone is used prematurely to transform the endometrium, it can alter the gene expression profile and distort the results. Doctors must strictly control the timing of medication.
- Endometrial thickness and morphology still need evaluation: ERT only reflects receptivity at the gene expression level and does not replace ultrasound assessment of endometrial thickness, morphology, blood flow, and peristalsis. Normal gene expression but abnormal endometrial morphology (e.g., thin endometrium, unclear triple-line sign) can also affect implantation.
- Different testing platforms have different reference ranges: The ERT/ERA platforms used in China have their own reference models and interpretation standards, and results are not directly interchangeable. It is recommended to complete testing and subsequent transfer plan adjustments on the same platform.
- Results from a single cycle do not represent all cycles: Window displacement may not be fixed. Some patients may show different results in different cycles (natural cycle vs. HRT cycle). If conditions permit, evaluation can be performed in both types of cycles.
Specific Process and Timeline for ERT Testing
From deciding to undergo ERT to obtaining results and formulating a transfer plan, the following steps are typically involved:
| Step | Specific Content | Time Required |
|---|---|---|
| 1. Doctor Evaluation and Cycle Selection | The reproductive specialist comprehensively reviews the patient's history, previous transfer outcomes, and test results to determine suitability for ERT and selects the testing cycle (natural or HRT cycle). | 1 outpatient visit |
| 2. Endometrial Preparation and Monitoring | Endometrial preparation is performed according to the selected cycle protocol. Endometrial development is monitored via ultrasound and hormone testing to determine the timing of endometrial sampling. | 10–14 days |
| 3. Endometrial Biopsy | A small amount of endometrial tissue is collected in the clinic or operating room using a disposable sampler (usually no anesthesia required, similar to a uterine cavity examination) and sent for testing. | 5–10 minutes |
| 4. Laboratory Testing | The sample is sent to the testing center for RNA extraction, gene expression analysis, and comparison with the reference model. | 7–14 business days |
| 5. Result Interpretation and Plan Adjustment | Based on the ERT report and the patient's condition, the doctor determines the transfer time (earlier, standard, or later) and formulates a personalized transfer plan. | 1 outpatient visit |
| 6. Execution of the Transfer Cycle | Endometrial preparation and embryo transfer are carried out according to the adjusted plan. | 12–18 days |
The entire process, from initial evaluation to completing the transfer, usually takes 2 to 3 menstrual cycles. If the ERT result shows that the window of implantation is consistent with the standard protocol, transfer can proceed directly according to the original plan without an additional cycle.
How Do Reproductive Specialists View the Clinical Value of ERT?
As a reproductive specialist, my view is: ERT is a useful tool in the evaluation system for recurrent implantation failure, but it is not a "magic key." In clinical decision-making, we typically use it as the third or fourth step—first ruling out uterine factors (hysteroscopy, endometrial biopsy pathology), immune/coagulation factors, and embryo factors before considering ERT.
Current evidence-based medicine indicates that for strictly selected patients with recurrent implantation failure, adjusting the transfer time based on ERT results can increase the implantation rate from 15%–20% to 30%–40% (with significant variation across different studies). However, about half of patients still fail to implant even after adjusting the window, suggesting other undiscovered causes.
The value of ERT lies in helping some patients with "window displacement" find direction, but it cannot solve all implantation problems. I usually tell patients: "Think of ERT as a detailed functional exploration of the endometrium, not a guarantee of success."
From a technical perspective, the consistency between Chinese ERT platform results and foreign ERA platform results is between 80% and 90%. However, China lacks large-scale, multi-center clinical validation data, and there are differences in interpretation experience and subsequent plan adjustment strategies among centers. Therefore, it is more important to choose a reproductive center with experience in ERT testing and a complete clinical pathway.
7 Most Frequently Asked Questions About ERT from Patients
| Question | Brief Answer |
|---|---|
| Are ERT and ERA the same thing? | Essentially the same; both test endometrial receptivity gene expression. ERA is a commercial test abroad (Igenomix), while ERT is a similar domestically developed technology in China. The testing principle and clinical use are basically the same, but the reference model and gene panel differ. |
| Is ERT testing painful? Is anesthesia needed? | Endometrial biopsy usually uses a disposable, thin, soft sampler. Most women experience mild discomfort similar to menstrual cramps, lasting 10–20 seconds. Anesthesia is generally not required, and hospitalization is not needed. |
| Will ERT affect the transfer in the same cycle? | The testing cycle requires endometrial sampling, so transfer is not suitable in the same cycle. It is usually recommended to rest for one cycle after the biopsy before starting the formal transfer cycle. However, the specific arrangement depends on the doctor's assessment of endometrial recovery. |
| How accurate is ERT? | Current data show that the accuracy of ERT in determining window displacement is about 75%–85% (using post-transfer implantation rate as the reference standard). False negatives and false positives exist, so it cannot completely replace clinical judgment. |
| Who should most consider ERT? | Patients with recurrent implantation failure (≥2 high-quality embryo transfers without implantation), especially those who have failed with PGT-normal blastocysts; and individuals with clear high-risk factors for window displacement (e.g., advanced age, thin endometrium, poor response to previous ovulation induction cycles). |
| How many times does ERT need to be done? | Most patients need it only once. If the ERT result clearly contradicts clinical judgment, or if the cycle type is changed (e.g., from HRT to natural cycle), repeat testing may be considered. However, the significance of repeated testing is not yet clear. |
| How much does ERT cost? Is it covered by medical insurance? | Currently, the cost of ERT testing in China ranges from 3,000 to 6,000 RMB, varying by platform and region. This test is not currently covered by the national medical insurance catalog and requires out-of-pocket payment. Some reproductive centers offer evaluation packages that include ERT. |
⚠ Risk Reminder ERT is an auxiliary testing technique and cannot replace a complete etiological screening for implantation failure. The test result only reflects the endometrial gene expression status at the time of sampling and does not represent the endometrial status of the entire cycle or future cycles. About 15%–25% of ERT results are inconsistent with actual clinical implantation outcomes. Therefore, doctors need to integrate information from ultrasound, hysteroscopy, pathology, immunology, and other sources for comprehensive decision-making. Do not over-adjust the plan based solely on ERT results.
Doctor's Advice If you are considering ERT, it is recommended to first complete the following basic evaluations: ① Hysteroscopy (to rule out endometrial adhesions, polyps, inflammation); ② Chronic endometritis testing (CD138 immunohistochemistry or microbial culture); ③ Embryo factor assessment (blastocyst morphology, PGT results); ④ Endocrine and metabolic status evaluation. If no clear cause is found after completing these evaluations, then discuss the necessity of ERT with your doctor. Choose a reproductive center with experience in ERT testing and a complete clinical pathway to avoid deviations in the testing or plan adjustment stages.
This content is based on clinical practice in assisted reproduction and published research evidence and does not constitute individualized medical advice. Please consult a licensed reproductive specialist for specific diagnosis and treatment plans.
Comments (0)